Squarepoint’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.73M | Buy |
107,385
+87,128
| +430% | +$4.96M | 0.01% | 1219 |
|
|
2025
Q4 | $856K | Sell |
20,257
-14,243
| -41% | -$797K | ﹤0.01% | 2745 |
|
|
2025
Q3 | $1.96M | Buy |
+34,500
| New | +$1.14M | ﹤0.01% | 2124 |
|
|
2025
Q1 | – | Sell |
-9,317
| Closed | -$130K | – | 5144 |
|
|
2024
Q4 | $130K | Buy |
+9,317
| New | +$164K | ﹤0.01% | 4628 |
|
|
2024
Q2 | – | Sell |
-2,585
| Closed | -$36.2K | – | 4456 |
|
|
2024
Q1 | $36.2K | Sell |
2,585
-5,959
| -70% | -$62.4K | ﹤0.01% | 3896 |
|
|
2023
Q4 | $72.4K | Buy |
+8,544
| New | +$64.7K | ﹤0.01% | 3803 |
|
|
2023
Q3 | – | Sell |
-54,320
| Closed | -$469K | – | 4087 |
|
|
2023
Q2 | $469K | Buy |
54,320
+8,952
| +20% | +$95.5K | ﹤0.01% | 2655 |
|
|
2023
Q1 | $478K | Buy |
45,368
+42,283
| +1,371% | +$1.28M | ﹤0.01% | 2330 |
|
|
2022
Q4 | $105K | Sell |
3,085
-5,763
| -65% | -$279K | ﹤0.01% | 2961 |
|
|
2022
Q3 | $425K | Buy |
+8,848
| New | +$526K | ﹤0.01% | 2279 |
|
|
2022
Q2 | – | Sell |
-9,615
| Closed | -$777K | – | 3209 |
|
|
2022
Q1 | $777K | Sell |
9,615
-1,094
| -10% | -$162K | ﹤0.01% | 1739 |
|
|
2021
Q4 | $2.17M | Buy |
10,709
+9,917
| +1,252% | +$2.15M | 0.01% | 1209 |
|
|
2021
Q3 | $213K | Sell |
792
-5,108
| -87% | -$1.23M | ﹤0.01% | 2450 |
|
|
2021
Q2 | $1.52M | Buy |
5,900
+4,587
| +349% | +$1.27M | 0.01% | 1346 |
|
|
2021
Q1 | $394K | Sell |
1,313
-821
| -38% | -$256K | ﹤0.01% | 2203 |
|
|
2020
Q4 | $544K | Sell |
2,134
-1,846
| -46% | -$477K | ﹤0.01% | 1756 |
|
|
2020
Q3 | $990K | Buy |
+3,980
| New | +$1.25M | 0.01% | 1004 |
|
|
2020
Q2 | – | Sell |
-5,156
| Closed | -$1.38M | – | 2422 |
|
|
2020
Q1 | $1.38M | Sell |
5,156
-2,996
| -37% | -$927K | 0.04% | 586 |
|
|
2019
Q4 | $2.64M | Sell |
8,152
-6,135
| -43% | -$1.78M | 0.02% | 745 |
|
|
2019
Q3 | $3.9M | Buy |
+14,287
| New | +$5.24M | 0.03% | 566 |
|
|
2019
Q1 | – | Sell |
-9,899
| Closed | -$4.88M | – | 2350 |
|
|
2018
Q4 | $4.88M | Sell |
9,899
-5,719
| -37% | -$3.45M | 0.06% | 415 |
|
|
2018
Q3 | $14.3M | Buy |
15,618
+11,775
| +306% | +$10.1M | 0.17% | 157 |
|
|
2018
Q2 | $2.81M | Buy |
+3,843
| New | +$4.43M | 0.04% | 536 |
|
|
2017
Q3 | – | Sell |
-916
| Closed | -$269K | – | 1790 |
|
|
2017
Q2 | $269K | Buy |
+916
| New | +$265K | 0.01% | 1179 |
|
|
2016
Q4 | – | Sell |
-1,469
| Closed | -$379K | – | 1869 |
|
|
2016
Q3 | $379K | Buy |
1,469
+589
| +67% | +$152K | 0.03% | 657 |
|
|
2016
Q2 | $188K | Sell |
880
-3,164
| -78% | -$707K | 0.01% | 905 |
|
|
2016
Q1 | $834K | Buy |
+4,044
| New | +$777K | 0.06% | 439 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Squarepoint's NKTR Position: Q1 2026 in Review
Squarepoint increased its Nektar Therapeutics (NKTR) stake by 430% in Q1 2026, buying an estimated $4.96M and bringing the position to 107,385 shares worth $7.73M. The position accounts for 0.01% of the portfolio, ranked #1219.
Squarepoint first reported a position in NKTR in Q1 2016 and has held it in 27 quarters since. The position peaked at $14.3M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Squarepoint held 107,385 shares of Nektar Therapeutics worth $7.73M as of Q1 2026.
- Squarepoint bought 87,128 Nektar Therapeutics shares in Q1 2026, an estimated $4.96M.
- Nektar Therapeutics made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1219 holding.
- Squarepoint first reported a position in Nektar Therapeutics in Q1 2016 and has held it in 27 quarters since.
- Squarepoint's Nektar Therapeutics position peaked at $14.3M in Q3 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.